KPRX — Kiora Pharmaceuticals Balance Sheet
0.000.00%
- $10.09m
- -$16.70m
- $16.02m
- 46
- 99
- 28
- 59
Annual balance sheet for Kiora Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-Q | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1.19 | 7.85 | 5.96 | 2.45 | 26.8 |
Net Total Receivables | 0.091 | 0.53 | 1.37 | 2.05 | 0.871 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.73 | 8.99 | 7.68 | 4.74 | 29.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.114 | 0.283 | 0.172 | 0.115 | 0.062 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 15.2 | 20.1 | 18.7 | 13.7 | 36.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.77 | 1.61 | 3.27 | 1.63 | 6.01 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.16 | 5.55 | 7.27 | 7.6 | 10.7 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 7 | 14.6 | 11.4 | 6.11 | 25.8 |
Total Liabilities & Shareholders' Equity | 15.2 | 20.1 | 18.7 | 13.7 | 36.5 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |